Tachykinin regulation of cholinergic transmission in the limbic/prefrontal territory of the rat dorsal striatum: implication of new neurokinine 1-sensitive receptor binding site and interaction with enkephalin/mu opioid receptor transmission

J Neurochem. 2007 Dec;103(6):2153-63. doi: 10.1111/j.1471-4159.2007.04944.x. Epub 2007 Oct 18.

Abstract

The tachykinin neurokinin 1 receptors (NK(1)Rs) regulation of acetylcholine release and its interaction with the enkephalin/mu opioid receptors (MORs) transmission was investigated in the limbic/prefrontal (PF) territory of the dorsal striatum. Using double immunohistochemistry, we first showed that in this territory, cholinergic interneurons contain tachykinin NK(1)Rs and co-express MORs in the last part of the light period (afternoon). In slices of the striatal limbic/PF territory, following suppression of the dopaminergic inhibitory control of acetylcholine release, application of the tachykinin NK(1)R antagonist, SSR240600, markedly reduced the NMDA-induced acetylcholine release in the morning but not in the afternoon when the enkephalin/MOR regulation is operational. In the afternoon, the NK(1)R antagonist response required the suppression of the enkephalin/MOR inhibitory control of acetylcholine release by betafunaltrexamine. The pharmacological profile of the tachykinin NK(1)R regulation tested by application of the receptor agonists [[Pro(9)]substance P, neurokinin A, neuropeptide K, and substance P(6-11)] and antagonists (SSR240600, GR205171, GR82334, and RP67580) indicated that the subtype of tachykinin NK(1)R implicated are the new NK(1)-sensitive receptor binding site. Therefore, in the limbic/PF territory of the dorsal striatum, endogenous tachykinin facilitates acetylcholine release via a tachykinin NK(1)R subtype. In the afternoon, the tachykinin/NK(1)R and the enkephalin/MOR transmissions interact to control cholinergic transmission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / metabolism
  • Animals
  • Binding Sites / drug effects
  • Binding Sites / physiology
  • Binding, Competitive / drug effects
  • Binding, Competitive / physiology
  • Cholinergic Fibers / metabolism*
  • Circadian Rhythm / drug effects
  • Circadian Rhythm / physiology
  • Enkephalins / metabolism
  • Limbic System / metabolism
  • Male
  • Morpholines / pharmacology
  • Narcotic Antagonists / pharmacology
  • Neostriatum / cytology
  • Neostriatum / metabolism*
  • Neural Pathways / metabolism
  • Neurokinin-1 Receptor Antagonists
  • Organ Culture Techniques
  • Piperidines / pharmacology
  • Prefrontal Cortex / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Neurokinin-1 / agonists
  • Receptors, Neurokinin-1 / metabolism*
  • Receptors, Opioid, mu / antagonists & inhibitors
  • Receptors, Opioid, mu / metabolism*
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology*
  • Tachykinins / agonists
  • Tachykinins / antagonists & inhibitors
  • Tachykinins / metabolism*

Substances

  • 2-(1-(2-(4-(2-(3,5-bis(trifluoromethyl)phenyl)acetyl)-2-(3,4-dichlorophenyl)-2-morpholinyl)ethyl)-4-piperidinyl)-2-methylpropanamide
  • Enkephalins
  • Morpholines
  • Narcotic Antagonists
  • Neurokinin-1 Receptor Antagonists
  • Piperidines
  • Receptors, Neurokinin-1
  • Receptors, Opioid, mu
  • Tachykinins
  • Acetylcholine